Loading...

TransBiotec

OTCPK:IMLE
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMLE
OTCPK
$724K
Market Cap
  1. Home
  2. US
  3. Tech
Company description

TransBiotec, Inc. develops non-invasive alcohol sensing systems. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • TransBiotec has significant price volatility in the past 3 months.
IMLE Share Price and Events
7 Day Returns
-38%
OTCPK:IMLE
0.7%
US Electronic
1.2%
US Market
1 Year Returns
-
OTCPK:IMLE
-0.3%
US Electronic
3%
US Market
IMLE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TransBiotec (IMLE) -38% 55% 106.7% - -65.6% -69%
US Electronic 0.7% 1.1% 21.2% -0.3% 59.3% 59.2%
US Market 1.2% 2.1% 14.6% 3% 39% 43.5%
1 Year Return vs Industry and Market
  • No trading data on IMLE.
  • No trading data on IMLE.
Price Volatility
IMLE
Industry
5yr Volatility vs Market

Value

 Is TransBiotec undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether TransBiotec is trading at an attractive price based on the cash flow it is expected to produce in the future. But as TransBiotec has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for TransBiotec. This is due to cash flow or dividend data being unavailable. The share price is $0.0062.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TransBiotec's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TransBiotec's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:IMLE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-12-31) in USD $-0.01
OTCPK:IMLE Share Price ** OTCPK (2019-03-19) in USD $0.01
United States of America Electronic Industry PE Ratio Median Figure of 92 Publicly-Listed Electronic Companies 19.54x
United States of America Market PE Ratio Median Figure of 3,058 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TransBiotec.

OTCPK:IMLE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:IMLE Share Price ÷ EPS (both in USD)

= 0.01 ÷ -0.01

-0.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TransBiotec is loss making, we can't compare its value to the US Electronic industry average.
  • TransBiotec is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does TransBiotec's expected growth come at a high price?
Raw Data
OTCPK:IMLE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Electronic Industry PEG Ratio Median Figure of 60 Publicly-Listed Electronic Companies 1.54x
United States of America Market PEG Ratio Median Figure of 2,103 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TransBiotec, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TransBiotec's assets?
Raw Data
OTCPK:IMLE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-12-31) in USD $-0.03
OTCPK:IMLE Share Price * OTCPK (2019-03-19) in USD $0.01
United States of America Electronic Industry PB Ratio Median Figure of 151 Publicly-Listed Electronic Companies 2.1x
United States of America Market PB Ratio Median Figure of 5,156 Publicly-Listed Companies 1.89x
OTCPK:IMLE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:IMLE Share Price ÷ Book Value per Share (both in USD)

= 0.01 ÷ -0.03

-0.23x

* Primary Listing of TransBiotec.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TransBiotec has negative assets, we can't compare the value of its assets to the US Electronic industry average.

Next steps:

  1. Take a look at our analysis of IMLE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Electronic industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess TransBiotec's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Electronic industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Electronic industry average (and greater than 0)? (1 check)
  5. TransBiotec has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TransBiotec expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TransBiotec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17%
Expected Electronic industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TransBiotec expected to grow at an attractive rate?
  • Unable to compare TransBiotec's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare TransBiotec's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare TransBiotec's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:IMLE Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Electronic Industry Earnings Growth Rate Market Cap Weighted Average 17%
United States of America Electronic Industry Revenue Growth Rate Market Cap Weighted Average 5.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:IMLE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:IMLE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2017-12-31 0 -1
2017-09-30 0 -1
2017-06-30 0 -1
2017-03-31 0 -1
2016-12-31 0 -1
2016-09-30 0 -1
2016-06-30 0 -1
2016-03-31 0 -1
2015-12-31 0 -1
2015-09-30 0 -1
2015-06-30 0 -1
2015-03-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if TransBiotec is high growth as no earnings estimate data is available.
  • Unable to determine if TransBiotec is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:IMLE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from TransBiotec Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:IMLE Past Financials Data
Date (Data in USD Millions) EPS *
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 -0.01
2015-12-31 -0.01
2015-09-30 -0.01
2015-06-30 -0.01
2015-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TransBiotec will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of IMLE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. TransBiotec's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Tech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access TransBiotec's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess TransBiotec's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TransBiotec has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TransBiotec performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TransBiotec's growth in the last year to its industry (Electronic).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TransBiotec does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare TransBiotec's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TransBiotec's 1-year growth to the US Electronic industry average as it is not currently profitable.
Earnings and Revenue History
TransBiotec's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TransBiotec Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:IMLE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-12-31 -0.64 0.31
2017-09-30 -0.63 0.52
2017-06-30 -0.81 0.49
2017-03-31 -0.92 0.43
2016-12-31 -0.60 0.40
2016-09-30 -0.85 0.41
2016-06-30 -0.72 0.46
2016-03-31 -0.74 0.46
2015-12-31 -0.69 0.45
2015-09-30 -0.58 0.43
2015-06-30 -0.62 0.40
2015-03-31 -0.66 0.45
2014-12-31 -0.74 0.51
2014-09-30 -0.45 0.55
2014-06-30 -0.12 0.62
2014-03-31 -0.52 0.69
2013-12-31 -0.76 0.78
2013-09-30 -1.92 1.19
2013-06-30 -2.31 1.17
2013-03-31 -1.91 1.09
2012-12-31 -3.55 2.89
2012-09-30 -3.12 2.60
2012-06-30 -3.13 2.66
2012-03-31 -2.97 2.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TransBiotec has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if TransBiotec has efficiently used its assets last year compared to the US Electronic industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TransBiotec improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess TransBiotec's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Electronic industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TransBiotec has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TransBiotec's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TransBiotec's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TransBiotec's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • TransBiotec has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TransBiotec's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • TransBiotec has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TransBiotec Company Filings, last reported 1 year ago.

OTCPK:IMLE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2017-12-31 -2.96 0.79 0.00
2017-09-30 -2.94 0.79 0.00
2017-06-30 -2.81 0.77 0.00
2017-03-31 -3.42 0.76 0.03
2016-12-31 -3.01 0.79 0.01
2016-09-30 -2.63 0.75 0.02
2016-06-30 -2.40 0.70 0.00
2016-03-31 -2.28 0.68 0.00
2015-12-31 -2.15 0.65 0.01
2015-09-30 -3.42 1.62 0.02
2015-06-30 -3.33 1.65 0.00
2015-03-31 -3.17 1.64 0.03
2014-12-31 -3.09 1.61 0.00
2014-09-30 -3.02 1.39 0.00
2014-06-30 -2.94 1.39
2014-03-31 -2.80 1.38
2013-12-31 -2.65 1.35
2013-09-30 -2.77 1.77 0.00
2013-06-30 -3.12 2.07
2013-03-31 -2.62 1.70
2012-12-31 -2.40 0.94 0.00
2012-09-30 -1.78 0.93 0.00
2012-06-30 -1.69 0.90 0.00
2012-03-31 -1.64 0.88 0.00
  • TransBiotec has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if TransBiotec's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TransBiotec has less than a year of cash runway based on current free cash flow.
  • TransBiotec has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26.4% each year.
X
Financial health checks
We assess TransBiotec's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TransBiotec has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TransBiotec's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TransBiotec dividends.
If you bought $2,000 of TransBiotec shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TransBiotec's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TransBiotec's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:IMLE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Electronic Industry Average Dividend Yield Market Cap Weighted Average of 38 Stocks 1.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2004 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TransBiotec has not reported any payouts.
  • Unable to verify if TransBiotec's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TransBiotec's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TransBiotec has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TransBiotec's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TransBiotec afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TransBiotec has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TransBiotec's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chuck Bennington
COMPENSATION $60,000
AGE 73
TENURE AS CEO 1.2 years
CEO Bio

Mr. Charles Warren Bennington, also known as Chuck, has been the Chairman of the Board at TransBiotec, Inc. since December 2006 and as its Director since April 2005. He has been Chief Executive Officer and Secretary at TransBiotec, Inc. since January 2018. He has been the Chief Executive Officer, President, Chief Financial Officer and Principal Accounting Officer at Imagine Media Ltd. since September 19, 2011. Mr. Bennington served as Interim Chief Financial Officer of TransBiotec, Inc. since April 2017 until 2018. Mr. Bennington served as the Chief Executive Officer, President, Chief Financial Officer and Principal Accounting Officer of TransBiotec, Inc from December 2006 to September 1, 2016 and as its Chief Operating Officer from May 2005 to September 1, 2016. He served as the Chief Executive Officer of TransBiotec Inc. From May 2005 to December 2006. He served as the Chief Operating Officer at TBT's. He has been a Director of Imagine Media Ltd. since September 19, 2011 and TBT since April 2005. Mr. Bennington holds a Degree in Finance and Banking from the University of Miami, Ohio.

CEO Compensation
  • Chuck's compensation has been consistent with company performance over the past year.
  • Chuck's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the TransBiotec management team in years:

1.2
Average Tenure
54.5
Average Age
  • The average tenure for the TransBiotec management team is less than 2 years, this suggests a new team.
Management Team

Chuck Bennington

TITLE
CEO, Secretary & Chairman of the Board
COMPENSATION
$60K
AGE
73
TENURE
1.2 yrs

Daljit Khangura

TITLE
COO & Director
AGE
51

Nick Noceti

TITLE
Interim Chief Financial Officer
AGE
46
TENURE
0.8 yrs

Michael Lanphere

TITLE
Vice President of Legal Affairs & General Counsel
AGE
58
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the TransBiotec board of directors in years:

8.8
Average Tenure
69
Average Age
  • The tenure for the TransBiotec board of directors is about average.
Board of Directors

Chuck Bennington

TITLE
CEO, Secretary & Chairman of the Board
COMPENSATION
$60K
AGE
73
TENURE
12.3 yrs

Daljit Khangura

TITLE
COO & Director
AGE
51
TENURE
5.3 yrs

Devadatt Mishal

TITLE
Director
AGE
69
TENURE
8.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess TransBiotec's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TransBiotec has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

TransBiotec, Inc. develops non-invasive alcohol sensing systems. It develops SOBR, a transdermal sensing system that detects blood alcohol levels through a person's skin. The company was founded in 2004 and is based in Santa Ana, California.

Details
Name: TransBiotec, Inc
IMLE
Exchange: OTCPK
Founded: 2004
$723,856
116,751,078
Website: http://www.transbiotec.com
Address: TransBiotec, Inc
400 North Tustin Avenue,
Suite 225,
Santa Ana,
California, 92705,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK IMLE Common Stock Pink Sheets LLC US USD 20. Sep 2011
Number of employees
Current staff
Staff numbers
0
TransBiotec employees.
Industry
Electronic Equipment and Instruments
Tech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/21 00:34
End of day share price update: 2019/03/19 00:00
Last earnings filing: 2019/02/06
Last earnings reported: 2017/12/31
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.